

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P176181

Serial No.

29-113,700

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant


Ashkenazi et al.

Filing Date

26 Jun 2000

Group

1646



FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
cw	1	417,563	10/10/91	EPO (ENGLISH ABSTRACT ATTACHED)				
	2	WO 89/03910	01/01/90	PCT				
	3	WO 92/03478	05/04/92	PCT				
	4	WO 92/17200	05/04/92	PCT				
	5	WO 97/11403	06/01/97	PCT				
	6	WO 97/23615	03/07/97	PCT (ENGLISH ABSTRACT ATTACHED)				
	7	WO 97/26428	17/07/97	PCT				
	8	WO 97/33499	18/09/97	PCT				
	9	WO 97/46646	11/01/97	PCT				
	10	WO 98/51793	19/11/98	PCT				
	11	WO 99/10484	04/03/99	PCT				
	12	WO 99/36535	22/07/99	PCT				

RECEIVED

DEC 29 2000

TECH CENTER 1600/2900

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

cw	13	Armitage et al., "Molecular and Biological characterization of a murine ligand for CD44" <u>Nature</u> 357(6373):80-82 (1992)
	14	Arufo et al., "CD44 is the Principal Cell Surface Receptor for Hyaluronate" <u>Cell</u> 61:1303-1313 (1990)
	15	Ashkenazi and Dixit, "Death receptors: signaling and modulation" <u>Science</u> 281(5331):1335-1338 (1998)
	16	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" <u>Proc. Natl. Acad. Sci. USA</u> 88:10335-10339 (1991)
	17	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993)
	18	Barr and Tomei, "Apoptosis and Its Role in Human Disease" <u>Bio. Technology</u> 12:487-493 (1994)
	19	Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)" <u>Immunity</u> 6:79-88 (1997)
	20	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990)
	21	Brojatsch et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis" <u>Cell</u> 87:345-355 (1996)
	22	Browning et al., "Lymphotoxin β , a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface" <u>Cell</u> 72:847-856 (1993)
	23	Cha et al., "1.3 Å Resolution Crystal Structure of Human TRAIL, a Cytokine with Selective Antitumor Activity" <u>Immunity</u> 11:253-261 (1999)
	24	Cha et al., "Expression, purification and crystallization of recombinant human TRAIL" <u>Acta Crystallographica, Section D: Biological Crystallography</u> 55:1101-1104 (1999)

Examiner

Eliak la zar - W36y

Date Considered

5/14/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#4

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P176181

Serial No

9,000,000

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

26 Jun 2000

Group

1636

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

25	Chang et al., "High-level secretion of human growth hormone by <i>Escherichia coli</i> " <u>Gene</u> 55:149-196 (1994)
26	Chicheportiche et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis" <u>Journal of Biological Chemistry</u> 272(51):32411-32416 (1997)
27	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNF α -1 and CD95" <u>Science</u> 274:990-992 (1996)
28	Christianson, D., "Structural Biology of Zinc" <u>Advances in Protein Chemistry</u> 42:281-355 (1991)
29	DeSper et al., "Construction of a Tandem trp-lac Promoter and a Hybrid trp-lac Promoter for Efficient and Controlled Expression of the Human Growth Hormone Gene in <i>Escherichia coli</i> " <u>Promoters: Structure and Function</u> , New York: Praeger pps. 462-481 (1992)
30	Degil-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family" <u>Journal of Experimental Medicine</u> 186(7):1165-1173 (1997)
31	Degil-Esposti et al., "The Novel Receptor TRAIL-R4 Induces NF- κ B and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain" <u>Immunity</u> 7:813-820 (1997)
32	Feese et al., "Cation-promoted association of a regulatory and target protein is controlled by protein phosphorylation" <u>Proc. Natl. Acad. Sci.</u> 91:3544-3548 (1994)
33	Garcia et al., "The <i>E. coli</i> dnaY Gene Encodes an Arginine Transfer RNA" <u>Cell</u> 45:453-459 (1986)
34	Golstein, P., "Cell Death: TRAIL and its Receptors" <u>Curr. Biol.</u> 7:R753-R753 (1997)
35	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor" <u>Molecular & Cellular Biology</u> 11:3020-3026 (1991)
36	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3378-3404 (1995)
37	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in <i>E. coli</i> " <u>J. Cell. Biochem.</u> (abstract only Supplement 15F; P 424) pps. 113 (1991)
38	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF α)" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1989)
39	Hymowitz et al., "A unique zinc-binding site revealed by the high-resolution X-ray structure of homotrimeric Apo2L TRAIL" <u>Biochemistry</u> 39(4):633-640 (2000)
40	Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L TRAIL in a complex with death receptor 5" <u>Molecular Cell</u> 4(4):563-571 (1999)
41	Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" <u>Cell</u> 66:233-243 (1991)
42	Johnson et al., "Expression and Structure of the Human NGF Receptor" <u>Cell</u> 47:545-554 (1986)
43	Karpusas et al., "The crystal structure of human interferon β at 2.2-A resolution" <u>Proc. Natl. Acad. Sci.</u> 94:11813-11818 (1997)
44	Kissoon et al., "A Death Domain Containing Receptor that Mediates Apoptosis" <u>Nature</u> 374:372-375 (1995)

Examiner

EW

Date Considered

3/14/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1761R1

Serial No.

09 63, 106

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

26 Jun 2001

Group

1636

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

45	Komno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" <u>Proc. Natl. Acad. Sci. USA</u> 87:6331-6335 (1990)
46	Komine et al., "Genomic Organization and Physical Mapping of the Transfer RNA Genes in <i>Escherichia coli</i> K12" <u>J. Mol. Biol.</u> 212:579-594 (1990)
47	Kunkel et al., "Rapid and Efficient Site-specific Mutagenesis Without Phenotypic Selection" <u>Methods in Enzymology</u> 154:367-382 (1987)
48	Kunkel, T., "Rapid and Efficient Site-specific Mutagenesis Without Phenotypic Selection" <u>Proc. Natl. Acad. Sci.</u> 82:488-492 (1985)
49	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific" <u>Proc. Natl. Acad. Sci. USA</u> 88:2830-2834 (1991)
50	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (1990)
51	MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL" <u>Journal of Biological Chemistry</u> 272(41):25417-25420 (1997)
52	Mallett et al., "Characterization of the MRG OX40 Antigen of Activated CD4 Positive T Lymphocytes - a Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9:1063-1068 (1990)
53	Marsters et al., "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain" <u>Current Biology</u> 7:1033-1036 (1997)
54	Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA" <u>Current Biology</u> 6(6):750-752 (1996)
55	Marsters et al., "Apo-1, a New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF- κ B" <u>Curr. Biol.</u> 6(12):1669-1676 (1996)
56	Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tumor Necrosis Factor (TNFR) Family, Interacts with Members of the TNFR-associated Factor Family and Activates the Transcription Factors NF- κ B and AP-1" <u>Journal of Biological Chemistry</u> 272(32):14039-14042 (1997)
57	Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo2" <u>Current Biology</u> 8(9):515-518 (1998)
58	Mongkolsapaya et al., "Cutting Edge Lymphocyte Inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL" <u>Journal of Immunology</u> 163(1):3-6 (1998)
59	Mongkolsapaya et al., "Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation" <u>Nature Structural Biology</u> 6(11):1048-1053 (Nov 1999)
60	Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF-NGF Receptor Family" <u>Cell</u> 87(3):427-436 (1996)
61	Mocentini et al., "A new member of the tumor necrosis factor nerve growth factor receptor family inhibits T cell receptor-induced apoptosis" <u>Proc. Natl. Acad. Sci.</u> 94(12):6216-6221 (1997)
62	Nopnar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs) The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor" <u>EMBO Journal</u> 9:3269-3278 (1993)
63	Owinski and Minor, "Processing of X-ray Diffraction Data Collected in Oscillation Mode" <u>Methods in Enzymology</u> , Carter and Sweet, San Diego, CA:Academic Press Vol. 276:307-326 (1997)
64	Owinski et al., <u>Proceedings of the CCP4 Study Weekend: Data Collection and Processing</u> , Sawyer et al., Daresbury, England Daresbury Laboratory pps. 56-62 (1993)

Examiner

EW

Date Considered

5/19/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

Atty Docket No.

P1761R1

Serial No.

09-603,866

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

65	Pan et al., "An Antagonist Decoy Receptor and a Death-domain Containing Receptor for TRAIL" <u>Science</u> 277:815-818 (1997)
66	Pan et al., "Identification and functional characterization of DR6, a novel death domain-containing TNF receptor" <u>FEBS Letters</u> 431(3):351-356 (1998)
67	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL" <u>Science</u> 276:111-113 (1997)
68	Pan et al., "TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling" <u>FEBS Letters</u> 434(1-2):41-46 (1998)
69	Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids" <u>European Journal of Haematology</u> 41:414-419 (1988)
70	Pitti et al., "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer" <u>Nature</u> 396(6712):699-703 (1998)
71	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)
72	Fadeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor" <u>Nature</u> 325:593-597 (1987)
73	Radhakrishnan et al., "Zinc mediated dimer of human interferon- α_2 revealed by X-ray crystallography" <u>Structure</u> 4:1453-1463 (1996)
74	Raman et al., "Crystal Structure of Constitutive Endothelial Nitric Oxide Synthase: A Paradigm for Pterin Function Involving a Novel Metal Center" <u>Cell</u> 95:939-950 (1998)
75	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (1990)
76	Schneider et al., "Characterization of two receptors for TRAIL" <u>FEBS Letters</u> 416:339-344 (1997)
77	Scholtissek and Gross, "A cloning cartridge of a t_0 terminator" <u>Nucl. Acids Res.</u> 15(7):3185 (1987)
78	Screaton et al., "LARD: A new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing" <u>Proc. Natl. Acad. Sci.</u> 94:4615-4619 (1997)
79	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL" <u>Current Biology</u> 7:693-696 (1997)
80	Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor α inhibitor" <u>Journal of Biological Chemistry</u> 264:11966-11973 (1989)
81	Sheldrick et al., "SHELXL: High-Resolution Refinement" <u>Methods in Enzymology</u> , San Diego:Academic Press Vol. 277:319-343 (1997)
82	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997)
83	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:309-319 (1997)
84	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 249:1319-1323 (1990)

Examiner

CW

Date Considered

5/14/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1761R1

Serial No.

19 6 3, 706

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

26 Jun 2000

Group

1636

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

85	Smith et al., "TNF Open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor" <u>Biochem. & Biophys. Res. Comm.</u> 176:335-342 (1991)
86	Somers et al., "The X-ray structure of a growth hormone-prolactin receptor complex" <u>Nature</u> 372:476-481 (1994)
87	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" <u>EMBO Journal</u> 8(5):1413-1418 (1989)
88	Steller, H., "Mechanisms and Genes of Cellular Suicide" <u>Science</u> 267:1445-1449 (1995)
89	Subelliffe, J., "Complete nucleotide sequence of the Escherichia coli plasmid pBR322" <u>Cold Spring Harbor Symposium on Quantitative Biology</u> 43:77-93 (1979)
90	Takao et al., "Novel DNA Polymorphism in the Mouse Tumor Necrosis Factor Receptors Type 1 and Type 2" <u>Immunogenetics</u> 37:199-203 (1993)
91	Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" <u>Virology</u> 184:370-382 (1991)
92	Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope fibroma virus genome" <u>Virology</u> 163:23-30 (1987)
93	Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL" <u>EMBO Journal</u> 16(17):5385-5397 (1997)
94	Welcher et al., "Nerve growth factor binding domain of the nerve growth factor receptor" <u>Proc. Natl. Acad. Sci. USA</u> 88:159-163 (1991)
95	Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" <u>Immunity</u> 3:673-682 (1995)
96	Wu et al., "KILLER DR5 is a DNA damage-inducible p53-regulated death receptor gene" <u>Nature Genetics</u> 17:141-143 (1997)
97	Yan and Chao, "Disruption of Cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding" <u>Journal of Biological Chemistry</u> 266:12109-12114 (1991)
98	Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor" <u>Journal of Experimental Medicine</u> 169:1747-1756 (1989)

RECEIVED

DEC 29 2000

CENTER 1600/2900


Examiner

EW

Date Considered

5/14/01

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1761R1

Serial No.

09-003,466

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

26 Jun 2000

Group

1636

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
EW	1	417,563	20.03.91	EPO (ENGLISH ABSTRACT ATTACHED)				
	2	WO 00/02900	20.01.00	PCT				
	3	WO 92/03473	05.03.92	PCT				
	4	WO 92/17230	15.10.92	PCT				
	5	WO 97/01633	16.01.97	PCT				
	6	WO 97/23615	03.07.97	PCT (ENGLISH ABSTRACT ATTACHED)				
	7	WO 97/25423	17.07.97	PCT				
	8	WO 97/33899	18.09.97	PCT				
	9	WO 97/46686	11.12.97	PCT				
	10	WO 98/51793	19.11.98	PCT				
	11	WO 99/10484	04.03.99	PCT				
	12	WO 99/36535	22.07.99	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

EW	13	Armitage et al., "Molecular and biological characterization of a murine ligand for CD44" <u>Nature</u> 357(6373):80-82 (1992)
	14	Arufo et al., "CD44 is the Principal Cell Surface Receptor for Hyaluronate" <u>Cell</u> 61:1303-1313 (1990)
	15	Ashkenazi and Dixit, "Death receptors: signaling and modulation" <u>Science</u> 281(5334):1300-1305 (1998)
	16	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" <u>Proc. Natl. Acad. Sci. USA</u> 88:10535-10539 (1991)
	17	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993)
	18	Barr and Tomel, "Apoptosis and Its Role in Human Disease" <u>Bio. Technology</u> 12:487-493 (1994)
	19	Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)" <u>Immunity</u> 6:79-88 (1997)
	20	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990)
	21	Brojatsch et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis" <u>Cell</u> 87:845-855 (1996)
	22	Browning et al., "Lymphotoxin β , a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface" <u>Cell</u> 72:847-856 (1993)
	23	Cha et al., "2.8 Å Resolution Crystal Structure of Human TRAIL, a Cytokine with Selective Antitumor Activity" <u>Immunity</u> 11:253-261 (1999)
	24	Cha et al., "Expression, purification and crystallization of recombinant human TRAIL" <u>Acta Crystallographica, Section D: Biological Crystallography</u> 55:1101-1104 (1999)

Examiner


EW

Date Considered

3/14/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

→ duplicate of paper #4 #15



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P176181

Serial No.

09 603,466

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

26 Jun 2000

Group

1836

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

25	Chang et al., "High-level secretion of human growth hormone by <i>Escherichia coli</i> " <u>Gene</u> 55:189-196 (1987)
26	Chicheportiche et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis" <u>Journal of Biological Chemistry</u> 272(51):32401-32410 (1997)
27	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" <u>Science</u> 274:990-992 (1996)
28	Christianson, D., "Structural Biology of Zinc" <u>Advances in Protein Chemistry</u> 42:261-355 (1991)
29	DeBoer et al., "Construction of a Tandem trp-lac Promoter and a Hybrid trp-lac Promoter for Efficient and Controlled Expression of the Human Growth Hormone Gene in <i>Escherichia coli</i> " <u>Promoters: Structure and Function</u> , New York: Praeger pps. 462-481 (1982)
30	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family" <u>Journal of Experimental Medicine</u> 186(7):1165-1170 (1997)
31	Degli-Esposti et al., "The Novel Receptor TRAIL-R4 Induces NF- κ B and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain" <u>Immunity</u> 7 813-820 (1997)
32	Feese et al., "Cation-promoted association of a regulatory and target protein is controlled by protein phosphorylation" <u>Proc. Natl. Acad.</u> 91:3544-3548 (1994)
33	Garcia et al., "The <i>E. coli</i> dnaY Gene Encodes an Arginine Transfer RNA" <u>Cell</u> 45:453-459 (1986)
34	Golstein, P., "Cell Death: TRAIL and its Receptors" <u>Curr. Biol.</u> 7:R753-R755 (1997)
35	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor" <u>Molecular & Cellular Biology</u> 11:3020-3026 (1991)
36	Gross and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3374-3404 (1995)
37	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in <i>E. coli</i> " <u>J. Cell. Biochem.</u> (abstract only Supplement 15F; P 424) pps. 113 (1991)
38	Hohnmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF α)" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1989)
39	Hymowitz et al., "A unique zinc-binding site revealed by the high-resolution X-ray structure of homotrimeric Apo2L/TRAIL" <u>Biochemistry</u> 39(4):633-640 (2000)
40	Hymowitz et al., "Triggering cell death: the crystal structure of Apo2L TRAIL in a complex with death receptor 5" <u>Molecular Cell</u> 4(4):563-571 (1999)
41	Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" <u>Cell</u> 66:233-243 (1991)
42	Johnson et al., "Expression and Structure of the Human NGF Receptor" <u>Cell</u> 47:545-554 (1986)
43	Karpusas et al., "The crystal structure of human interferon β at 2.2-Å resolution" <u>Proc. Natl. Acad. Sci.</u> 94:11813-11818 (1997)
44	Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" <u>Nature</u> 344:372-375 (1995)

Examiner


tww

Date Considered

1/14/01

*Examiner. Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
FEB 26 2001
TECH CENTER 1600/2500



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1761R1

Serial No.

39 633,866

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

16 Jun 2000

Group

1436

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

45	Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990)
46	Komine et al., "Genomic Organization and Physical Mapping of the Transfer RNA Genes in Escherichia coli K12" <u>J. Mol. Biol.</u> 212:579-599 (1990)
47	Funkel et al., "Rapid and Efficient Site-specific Mutagenesis Without Phenotypic Selection" <u>Methods in Enzymology</u> 154:367-382 (1987)
48	Funkel, T., "Rapid and Efficient Site-specific Mutagenesis Without Phenotypic Selection" <u>Proc. Natl. Acad. Sci.</u> 82:488-492 (1985)
49	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific" <u>Proc. Natl. Acad. Sci. USA</u> 88:2830-2834 (1991)
50	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (1990)
51	MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL" <u>Journal of Biological Chemistry</u> 272(41):25417-25420 (1997)
52	Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - a Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9:1063-1068 (1990)
53	Marsters et al., "A Novel Receptor for Apo2/ TRAIL Contains a Truncated Death Domain" <u>Current Biology</u> 7:1003-1006 (1997)
54	Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA" <u>Current Biology</u> 6(6):753-752 (1996)
55	Marsters et al., "Apo-1, a New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF- κ B" <u>Curr. Biol.</u> 6(12):1669-1676 (1996)
56	Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tumor Necrosis Factor (TNF) Family, Interacts with Members of the TNF-associated Factor Family and Activates the Transcription Factors NF- κ B and AP-1" <u>Journal of Biological Chemistry</u> 272(22):14029-14032 (1997)
57	Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3" <u>Current Biology</u> 8(9):525-528 (1998)
58	Mongkolsapaya et al., "Cutting Edge: Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL" <u>Journal of Immunology</u> 163(1):3-6 (1998)
59	Mongkolsapaya et al., "Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation" <u>Nature Structural Biology</u> 6(11):1048-1053 (Nov 1999)
60	Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" <u>Cell</u> 87(3):427-436 (1996)
61	Nocentini et al., "A new member of the tumor necrosis factor nerve growth factor receptor family inhibits T cell receptor-induced apoptosis" <u>Proc. Natl. Acad. Sci.</u> 94(10):6216-6221 (1997)
62	Nopnar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs) The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor" <u>EMBO Journal</u> 9:3269-3278 (1990)
63	Otwinowski and Minor, "Processing of X-ray Diffraction Data Collected in Oscillation Mode" <u>Methods in Enzymology</u> , Carter and Sweet, San Diego, CA: Academic Press Vol. 276:307-326 (1997)
*64	Otwinowski et al., <u>Proceedings of the QUP4 Study Weekend: Data Collection and Processing</u> Sawyer et al., Daresbury, England: Daresbury Laboratory pps. 56-62 (1993)


Examiner

tw

Date Considered

5/14/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

FEB 21 2001

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1761R1

Serial No.

09 603,846

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

26 Jun 2001

Group

1636

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

65	Pan et al., "An Antagonist Decoy Receptor and a Death-domain Containing Receptor for TRAIL" <u>Science</u> 277:815-818 (1997)
66	Pan et al., "Identification and functional characterization of DR6, a novel death domain-containing TNF receptor" <u>FEBS Letters</u> 431(3):351-356 (1998)
67	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL" <u>Science</u> 276:111-113 (1997)
68	Pan et al., "TRUND5, a new member of the TRAIL receptor family that antagonizes TRAIL signalling" <u>FEBS Letters</u> 424(1-1):41-45 (1998)
69	Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids" <u>European Journal of Haematology</u> 41:414-419 (1988)
70	Pitti et al., "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer" <u>Nature</u> 396(6712):699-703 (1998)
71	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)
72	Sadeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor" <u>Nature</u> 325:593-597 (1987)
73	Radhakrishnan et al., "Zinc mediated dimer of human interferon- α_2 revealed by X-ray crystallography" <u>Structure</u> 4:1453-1463 (1996)
74	Saman et al., "Crystal Structure of Constitutive Endothelial Nitric Oxide Synthase: A Paradigm for Pterin Function Involving a Novel Metal Center" <u>Cell</u> 95:939-950 (1993)
75	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (1990)
76	Schneider et al., "Characterization of two receptors for TRAIL" <u>FEBS Letters</u> 416:329-334 (1997)
77	Scholtissek and Grosse, "A cloning cartridge of λ to terminator" <u>Nucl. Acids Res.</u> 15(7):3185 (1987)
78	Screaton et al., "LARD: A new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing" <u>Proc. Natl. Acad. Sci.</u> 94:4615-4619 (1997)
79	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL" <u>Current Biology</u> 7:693-696 (1997)
80	Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor α inhibitor" <u>Journal of Biological Chemistry</u> 264:11966-11973 (1989)
81	Sheldrick et al., "SHELXL: High-Resolution Refinement" <u>Methods in Enzymology</u> , San Diego:Academic Press Vol. 277:319-343 (1997)
82	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997)
83	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:319-319 (1997)
84	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 248:1029-1033 (1990)

Examiner

ew

Date Considered

5/14/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FEB 21 2001

U.S. Dept. of Commerce
Patent and Trademark Office

RESULTS

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840. 84

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 26

Group

1636

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

| | |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 45 | Smith et al., "T2 Open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor" <u>Biochem. & Biophys. Res. Comm.</u> 176:335-342 (1991) |
| 46 | Somers et al., "The X-ray structure of a growth hormone-prolactin receptor complex" <u>Nature</u> 372:478-481 (1994) |
| 47 | Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" <u>EMBO Journal</u> 8(5):1403-1410 (1989) |
| 48 | Steller, H., "Mechanisms and Genes of Cellular Suicide" <u>Science</u> 267:1445-1449 (1995) |
| 49 | Sutcliffe, J., "Complete nucleotide sequence of the Escherichia coli plasmid pBR322" <u>Cold Spring Harbor Symposia on Quantitative Biology</u> 43:77-90 (1979) |
| 90 | Takao et al., "Novel DNA Polymorphism in the Mouse Tumor Necrosis Factor Receptors Type 1 and Type 2" <u>Immunogenetics</u> 37:199-203 (1993) |
| 91 | Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" <u>Virology</u> 134:370-382 (1991) |
| 92 | Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope fibroma virus genome" <u>Virology</u> 160:20-30 (1987) |
| 93 | Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL" <u>EMBO Journal</u> 16(17):5386-5397 (1997) |
| 94 | Welcher et al., "Nerve growth factor binding domain of the nerve growth factor receptor" <u>Proc. Natl. Acad. Sci. USA</u> 88:159-163 (1991) |
| 95 | Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" <u>Immunity</u> 3:673-682 (1995) |
| 96 | Wu et al., "KILLER/DR5 is a DNA damage-inducible p33 regulated death receptor gene" <u>Nature Genetics</u> 17:141-143 (1997) |
| 97 | Yan and Chao, "Disruption of Cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding" <u>Journal of Biological Chemistry</u> 266:12099-12104 (1991) |
| 98 | Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor" <u>Journal of Experimental Medicine</u> 169:1747-1756 (1989) |

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. *Chlorophyll a* (Chl *a*)

| Group | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 |
|-------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|-----|
| 1 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 |

1646

[illegible]

5/14/02

77

SERIAL NO.
09/603,866

FILING DATE
June 26, 2000

GROUP
To be assigned

1646

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|--|--|--|
| | | |
| | | |
| | | |

EXAMINER

clari la rou - wsky

DATE CONSIDERED

5/14/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

8